NZ615270A - Phosphoramidate derivatives of 5 - fluoro - 2 ‘ - deoxyuridine for use in the treatment of cancer - Google Patents
Phosphoramidate derivatives of 5 - fluoro - 2 ‘ - deoxyuridine for use in the treatment of cancer Download PDFInfo
- Publication number
- NZ615270A NZ615270A NZ615270A NZ61527012A NZ615270A NZ 615270 A NZ615270 A NZ 615270A NZ 615270 A NZ615270 A NZ 615270A NZ 61527012 A NZ61527012 A NZ 61527012A NZ 615270 A NZ615270 A NZ 615270A
- Authority
- NZ
- New Zealand
- Prior art keywords
- deoxyuridine
- fluoro
- cancer
- treatment
- phosphoramidate derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
- C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
- C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
- C07F9/65842—Cyclic amide derivatives of acids of phosphorus, in which one nitrogen atom belongs to the ring
- C07F9/65844—Cyclic amide derivatives of acids of phosphorus, in which one nitrogen atom belongs to the ring the phosphorus atom being part of a five-membered ring which may be condensed with another ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1103582.1A GB201103582D0 (enExample) | 2011-03-01 | 2011-03-01 | |
| GBGB1105660.3A GB201105660D0 (en) | 2011-04-01 | 2011-04-01 | Chemical compounds |
| PCT/GB2012/050457 WO2012117246A1 (en) | 2011-03-01 | 2012-02-29 | Phosphoramidate derivatives of 5 - fluoro - 2 ' - deoxyuridine for use in the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ615270A true NZ615270A (en) | 2015-09-25 |
Family
ID=45841523
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ615270A NZ615270A (en) | 2011-03-01 | 2012-02-29 | Phosphoramidate derivatives of 5 - fluoro - 2 ‘ - deoxyuridine for use in the treatment of cancer |
Country Status (28)
| Country | Link |
|---|---|
| US (7) | US8933053B2 (enExample) |
| EP (4) | EP3447061B1 (enExample) |
| JP (1) | JP5978232B2 (enExample) |
| KR (1) | KR101885940B1 (enExample) |
| CN (2) | CN104974206B (enExample) |
| AU (1) | AU2012223012C1 (enExample) |
| BR (1) | BR112013021986B1 (enExample) |
| CA (1) | CA2828326C (enExample) |
| CL (1) | CL2013002517A1 (enExample) |
| CY (2) | CY1117445T1 (enExample) |
| DK (3) | DK3447061T3 (enExample) |
| ES (4) | ES2686219T3 (enExample) |
| HR (2) | HRP20160346T1 (enExample) |
| HU (2) | HUE060127T2 (enExample) |
| IL (1) | IL228169A (enExample) |
| LT (1) | LT3447061T (enExample) |
| MX (1) | MX339822B (enExample) |
| NZ (1) | NZ615270A (enExample) |
| PH (2) | PH12013501723A1 (enExample) |
| PL (3) | PL3031812T3 (enExample) |
| PT (2) | PT3447061T (enExample) |
| RS (2) | RS54776B1 (enExample) |
| RU (1) | RU2614406C2 (enExample) |
| SG (1) | SG192841A1 (enExample) |
| SI (2) | SI3447061T1 (enExample) |
| SM (2) | SMT202100715T1 (enExample) |
| WO (1) | WO2012117246A1 (enExample) |
| ZA (2) | ZA201306468B (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201016855D0 (en) | 2010-10-06 | 2010-11-17 | Nucana Biomed Ltd | Chemical compounds |
| DK3447061T3 (da) * | 2011-03-01 | 2022-01-03 | NuCana plc | Farmaceutisk formulering omfattende et phosphoramidatderivat af 5-fluor-2'-deoxyuridin til anvendelse i cancerbehandling |
| HUE044605T2 (hu) * | 2012-11-16 | 2019-11-28 | Univ College Cardiff Consultants Ltd | RP/SP gemcitabin-[fenil-(benziloxi-L-alaninil)]-foszfát keveréke |
| WO2015013352A2 (en) * | 2013-07-25 | 2015-01-29 | Patel Hasmukh B | Nucleoside phosphoramidates and phosphoramidites |
| CN104447923B (zh) * | 2013-09-23 | 2018-03-30 | 中国药科大学 | 2’‑脱氧‑2’‑氟‑2’‑甲基核苷衍生物及其制备方法与在制药中的用途 |
| RU2553996C1 (ru) * | 2013-11-27 | 2015-06-20 | Андрей Александрович Иващенко | Замещенные (2r,3r,5r)-3-гидрокси-(5-пиримидин-1-ил)тетрагидрофуран-2-илметил арил фосфорамидаты |
| JP6783224B2 (ja) | 2014-04-04 | 2020-11-11 | デル マー ファーマシューティカルズ | 肺の非小細胞癌腫及び卵巣癌を処置するためのジアンヒドロガラクチトール及びその類縁体又は誘導体の使用 |
| AU2015265607A1 (en) * | 2014-05-28 | 2016-11-17 | Idenix Pharmaceuticals Llc | Nucleoside derivatives for the treatment of cancer |
| CN105153257B (zh) * | 2014-06-12 | 2019-03-05 | 正大天晴药业集团股份有限公司 | 索非布韦的制备方法 |
| KR102563040B1 (ko) | 2014-06-25 | 2023-08-02 | 뉴카나 피엘씨 | 젬시타빈 전구 약물 |
| PL225283B1 (pl) * | 2014-07-24 | 2017-03-31 | Univ Im Adama Mickiewicza W Poznaniu | Pochodne 2,3’-anhydro-2’-deoksy-5-fluorourydyny o działaniu cytotoksycznym, sposób wytwarzania i zastosowanie |
| CN111909231B (zh) | 2014-11-28 | 2025-10-17 | 努卡那有限公司 | 作为抗癌化合物的新的2’和/或5’-氨基酸酯氨基磷酸酯3’-脱氧腺苷衍生物 |
| GEP20217282B (en) | 2015-03-06 | 2021-08-10 | Atea Pharmaceuticals Inc | β-D-2'-DEOXY-2'α-FLUORO-2'-β-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT |
| HK1252245A1 (zh) * | 2015-05-27 | 2019-05-24 | Idenix Pharmaceuticals Llc | 用於治疗癌症的核苷酸 |
| CA3005444A1 (en) * | 2015-11-16 | 2017-05-26 | Ichorion Therapeutics, Inc. | Nucleic acid prodrugs |
| GB201522764D0 (en) | 2015-12-23 | 2016-02-03 | Nucana Biomed Ltd | Formulations of phosphate derivatives |
| GB201609600D0 (en) * | 2016-06-01 | 2016-07-13 | Nucuna Biomed Ltd | Cancer treatments |
| GB201609601D0 (en) | 2016-06-01 | 2016-07-13 | Nucana Biomed Ltd | Phosphoramidate compounds |
| WO2018013937A1 (en) | 2016-07-14 | 2018-01-18 | Atea Pharmaceuticals, Inc. | Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection |
| PT3512863T (pt) | 2016-09-07 | 2022-03-09 | Atea Pharmaceuticals Inc | Nucleótidos de purina 2'-substituídos-n6-substituídos para tratamento de vírus de rna |
| EP3538124A4 (en) | 2016-11-13 | 2020-07-22 | Imagine Pharma | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DIABETES, HYPERTENSION AND HYPERCHOLESTEROLEMIA |
| AU2017378959B2 (en) | 2016-12-23 | 2021-09-09 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Nucleoside phosphate compound and preparation method and use thereof |
| RU2644156C1 (ru) * | 2017-02-28 | 2018-02-08 | Александр Васильевич Иващенко | Пролекарство ингибитора NS5B HCV полимеразы, способ его получения и применения |
| GB201709471D0 (en) | 2017-06-14 | 2017-07-26 | Nucana Biomed Ltd | Diastereoselective synthesis of hosphate derivatives |
| JP2020530035A (ja) * | 2017-08-08 | 2020-10-15 | スン・ヤット−セン・ユニバーシティＳｕｎ Ｙａｔ−Ｓｅｎ Ｕｎｉｖｅｒｓｉｔｙ | 多剤耐性腫瘍を治療するための方法および組成物 |
| GB201713916D0 (en) * | 2017-08-30 | 2017-10-11 | Nucana Biomed Ltd | Treatment regimens |
| GB201715011D0 (en) | 2017-09-18 | 2017-11-01 | Nucana Biomed Ltd | Floxuridine synthesis |
| GB201720279D0 (en) | 2017-12-05 | 2018-01-17 | Nucana Biomed Ltd | Anticancer compounds |
| CN111836823B (zh) * | 2018-03-09 | 2023-06-30 | 国立研究开发法人科学技术振兴机构 | β修饰磷酸化合物前体、β修饰磷酸化合物、反应阻碍剂和包含这些化合物的医药品以及反应阻碍方法 |
| CN110387226A (zh) * | 2018-04-20 | 2019-10-29 | 天津大学 | 一种用于检测肿瘤的荧光探针及用途 |
| US12221649B2 (en) | 2018-11-30 | 2025-02-11 | The University Of Tokyo | Fluorescent probe for detecting carboxypeptidase activity |
| GB201904544D0 (en) | 2019-04-01 | 2019-05-15 | NuCana plc | Anticancer compounds |
| CN110840907B (zh) * | 2019-08-16 | 2022-11-25 | 南京医科大学 | 一类自由基敏感的尿嘧啶类ProTide前药及其药物用途 |
| US10874687B1 (en) | 2020-02-27 | 2020-12-29 | Atea Pharmaceuticals, Inc. | Highly active compounds against COVID-19 |
| WO2021173713A1 (en) | 2020-02-27 | 2021-09-02 | Atea Pharmaceuticals, Inc. | Highly active compounds against covid-19 |
| WO2022047400A1 (en) * | 2020-08-31 | 2022-03-03 | Emory University | 5'-substituted nucleoside monophosphates, prodrugs thereof, and uses related thereto |
| CN120584123A (zh) | 2022-12-07 | 2025-09-02 | 努卡那有限公司 | 核苷衍生物nuc-3373的合成 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2802005A (en) | 1957-08-06 | S-eluorourace | ||
| US1002239A (en) | 1902-04-11 | 1911-09-05 | Stromberg Carlson Telephone | Telephone system. |
| US2945038A (en) | 1956-09-26 | 1960-07-12 | Hoffmann La Roche | 5-fluorocytosine and preparation thereof |
| US3201387A (en) | 1963-09-18 | 1965-08-17 | Heidelberger Charles | 5-trifluoromethyluracil, derivatives thereof, and processes for preparing the same |
| US3792039A (en) | 1971-12-27 | 1974-02-12 | Miles Lab | Poly 2'-fluoro-2'-deoxyuridylic acid |
| DD279248A1 (de) | 1989-01-01 | 1990-05-30 | Akad Wissenschaften Ddr | Verfahren zur herstellung von 2',3'-didesoxythymidin-5'-diamidophosphaten |
| GB9505025D0 (en) * | 1995-03-13 | 1995-05-03 | Medical Res Council | Chemical compounds |
| RU2197964C2 (ru) * | 1995-04-12 | 2003-02-10 | Дзе Проктер Энд Гэмбл Компани | Фармацевтическая композиция, композиция стандартной лекарственной формы и способ лечения злокачественных новообразований, опухолей и вирусных инфекций |
| US7462605B2 (en) | 1998-01-23 | 2008-12-09 | Celmed Oncology (Usa), Inc. | Phosphoramidate compounds and methods of use |
| AU753155B2 (en) * | 1998-01-23 | 2002-10-10 | Kiadis Pharma Intellectual Property B.V. | Enzyme catalyzed therapeutic agents |
| EP1200455B1 (en) | 1999-07-22 | 2009-04-22 | Celmed Oncology (USA), Inc. | Enzyme catalyzed therapeutic activation |
| DE10109657A1 (de) | 2001-02-28 | 2002-09-05 | Menarini Ricerche Spa | Verfahren zur Herstellung von (E)-5-(2-Bromvinyl)-2`-desoxyuridin |
| EP1404694A1 (en) | 2001-06-21 | 2004-04-07 | Glaxo Group Limited | Nucleoside compounds in hcv |
| GB0317009D0 (en) * | 2003-07-21 | 2003-08-27 | Univ Cardiff | Chemical compounds |
| CA2589935A1 (en) | 2004-12-09 | 2006-06-15 | Regents Of The University Of Minnesota | Nucleosides with antiviral and anticancer activity |
| GB0505781D0 (en) | 2005-03-21 | 2005-04-27 | Univ Cardiff | Chemical compounds |
| JP2009504704A (ja) | 2005-08-15 | 2009-02-05 | エフ．ホフマン−ラ ロシュ アーゲー | 抗ウイルス４′−置換プロヌクレオチドホスホルアミダート |
| WO2007056596A2 (en) | 2005-11-09 | 2007-05-18 | Wayne State University | Phosphoramidate derivatives of fau |
| US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
| TWI583692B (zh) | 2009-05-20 | 2017-05-21 | 基利法瑪席特有限責任公司 | 核苷磷醯胺 |
| CN101922935B (zh) | 2010-07-16 | 2012-07-18 | 北京大学 | 一种最小互易结构干涉型全光纤陀螺仪 |
| EA025311B1 (ru) | 2010-07-19 | 2016-12-30 | Гайлид Сайэнсиз, Инк. | Способы получения диастереомерно чистых фосфорамидатных пролекарств |
| GEP20156313B (en) | 2010-09-22 | 2015-07-10 | Alios Biopharma Inc | Substituted nucleotide analogs |
| WO2012040126A1 (en) | 2010-09-22 | 2012-03-29 | Alios Biopharma, Inc. | Substituted nucleotide analogs |
| WO2012048013A2 (en) | 2010-10-06 | 2012-04-12 | Inhibitex, Inc. | Phosphorodiamidate derivatives of guanosine nucleoside compounds for treatment of viral injections |
| GB201016855D0 (en) | 2010-10-06 | 2010-11-17 | Nucana Biomed Ltd | Chemical compounds |
| ES2558779T3 (es) | 2011-03-01 | 2016-02-08 | Janssen Pharmaceutica, N.V. | Derivados de 6,7-dihidro-pirazolo[1,5-a]piracin-4-ilamina útiles como inhibidores de ß-secretasa (BACE) |
| DK3447061T3 (da) * | 2011-03-01 | 2022-01-03 | NuCana plc | Farmaceutisk formulering omfattende et phosphoramidatderivat af 5-fluor-2'-deoxyuridin til anvendelse i cancerbehandling |
| PT3119794T (pt) | 2014-06-25 | 2018-01-15 | Nucana Biomed Ltd | Formulação que compreende um pró-fármaco de gemcitabina |
| CN111909231B (zh) | 2014-11-28 | 2025-10-17 | 努卡那有限公司 | 作为抗癌化合物的新的2’和/或5’-氨基酸酯氨基磷酸酯3’-脱氧腺苷衍生物 |
| KR20180021697A (ko) | 2015-05-14 | 2018-03-05 | 뉴카나 피엘씨 | 암 치료 |
| GB201522764D0 (en) | 2015-12-23 | 2016-02-03 | Nucana Biomed Ltd | Formulations of phosphate derivatives |
| GB201609600D0 (en) | 2016-06-01 | 2016-07-13 | Nucuna Biomed Ltd | Cancer treatments |
| GB201709471D0 (en) | 2017-06-14 | 2017-07-26 | Nucana Biomed Ltd | Diastereoselective synthesis of hosphate derivatives |
-
2012
- 2012-02-29 DK DK18178715.1T patent/DK3447061T3/da active
- 2012-02-29 HU HUE18178715A patent/HUE060127T2/hu unknown
- 2012-02-29 RS RS20160211A patent/RS54776B1/sr unknown
- 2012-02-29 ES ES16150494.9T patent/ES2686219T3/es active Active
- 2012-02-29 PT PT181787151T patent/PT3447061T/pt unknown
- 2012-02-29 HR HRP20160346TT patent/HRP20160346T1/hr unknown
- 2012-02-29 EP EP18178715.1A patent/EP3447061B1/en active Active
- 2012-02-29 JP JP2013555935A patent/JP5978232B2/ja active Active
- 2012-02-29 US US14/000,682 patent/US8933053B2/en active Active
- 2012-02-29 SM SM20210715T patent/SMT202100715T1/it unknown
- 2012-02-29 ES ES18178715T patent/ES2903097T3/es active Active
- 2012-02-29 EP EP12709146.0A patent/EP2681227B1/en active Active
- 2012-02-29 CN CN201510329656.2A patent/CN104974206B/zh active Active
- 2012-02-29 KR KR1020137025749A patent/KR101885940B1/ko active Active
- 2012-02-29 RU RU2013143862A patent/RU2614406C2/ru active
- 2012-02-29 EP EP16150494.9A patent/EP3031812B1/en active Active
- 2012-02-29 PT PT16150494T patent/PT3031812T/pt unknown
- 2012-02-29 ES ES21209926T patent/ES3039965T3/es active Active
- 2012-02-29 PL PL16150494T patent/PL3031812T3/pl unknown
- 2012-02-29 CN CN201280010761.4A patent/CN103403013B/zh active Active
- 2012-02-29 DK DK16150494.9T patent/DK3031812T3/en active
- 2012-02-29 WO PCT/GB2012/050457 patent/WO2012117246A1/en not_active Ceased
- 2012-02-29 SG SG2013062823A patent/SG192841A1/en unknown
- 2012-02-29 SI SI201231972T patent/SI3447061T1/sl unknown
- 2012-02-29 HU HUE12709146A patent/HUE029022T2/en unknown
- 2012-02-29 BR BR112013021986-6A patent/BR112013021986B1/pt active IP Right Grant
- 2012-02-29 ES ES12709146.0T patent/ES2569185T3/es active Active
- 2012-02-29 DK DK12709146.0T patent/DK2681227T3/da active
- 2012-02-29 MX MX2013009815A patent/MX339822B/es active IP Right Grant
- 2012-02-29 LT LTEP18178715.1T patent/LT3447061T/lt unknown
- 2012-02-29 CA CA2828326A patent/CA2828326C/en active Active
- 2012-02-29 NZ NZ615270A patent/NZ615270A/en unknown
- 2012-02-29 AU AU2012223012A patent/AU2012223012C1/en active Active
- 2012-02-29 RS RS20211549A patent/RS62721B1/sr unknown
- 2012-02-29 PH PH1/2013/501723A patent/PH12013501723A1/en unknown
- 2012-02-29 SI SI201230488T patent/SI2681227T1/sl unknown
- 2012-02-29 PL PL12709146T patent/PL2681227T3/pl unknown
- 2012-02-29 PL PL18178715T patent/PL3447061T3/pl unknown
- 2012-02-29 HR HRP20211967TT patent/HRP20211967T1/hr unknown
- 2012-02-29 EP EP21209926.1A patent/EP4023299B1/en active Active
-
2013
- 2013-08-28 IL IL228169A patent/IL228169A/en active IP Right Grant
- 2013-08-30 CL CL2013002517A patent/CL2013002517A1/es unknown
- 2013-09-09 ZA ZA2013/06468A patent/ZA201306468B/en unknown
-
2014
- 2014-12-04 US US14/560,097 patent/US9221866B2/en active Active
- 2014-12-09 ZA ZA2014/09013A patent/ZA201409013B/en unknown
-
2015
- 2015-03-05 PH PH12015500485A patent/PH12015500485B1/en unknown
- 2015-11-17 US US14/943,555 patent/US9655915B2/en active Active
-
2016
- 2016-04-27 CY CY20161100360T patent/CY1117445T1/el unknown
- 2016-05-06 SM SM201600132T patent/SMT201600132B/it unknown
-
2017
- 2017-04-18 US US15/489,884 patent/US10022390B2/en active Active
-
2018
- 2018-06-28 US US16/021,103 patent/US10993957B2/en active Active
-
2021
- 2021-04-06 US US17/223,241 patent/US11559542B2/en active Active
- 2021-12-17 CY CY20211101114T patent/CY1124871T1/el unknown
-
2023
- 2023-01-11 US US18/095,937 patent/US11925658B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12013500005A1 (en) | Indolizine derivatives, process for the preparation thereof and therapeutic use thereof | |
| PH12017502141A1 (en) | Compounds and their methods of use | |
| MX2014012477A (es) | Inhibidores pirrolopirazona de tanquirasa. | |
| MY184101A (en) | Indoles | |
| NZ597517A (en) | 5-fluoropyrimidinone derivatives | |
| PH12014502169A1 (en) | N-cyclylamides as nematicides | |
| IL245062B (en) | History of 1-(5-tert-butyl-2-aryl-pyrazol-3-yl)-3-[2-fluoro-4-[(3-oxo-h4-pyrido[3,2-b]pyrazine-8 -Il)oxy]phenyl]urea as raf inhibitors for cancer treatment | |
| MX2013010898A (es) | Novedoso derivados de la pirimidina. | |
| MX343561B (es) | Compuestos de imidazolpiridazina. | |
| MX352975B (es) | Piridina y derivados de pirazina. | |
| MX352928B (es) | Compuestos de piridazina-amida. | |
| MX360404B (es) | Compuestos para inhibir la proliferacion celular en canceres transmitidos por egfr. | |
| PH12013501600A1 (en) | Novel heterocyclic derivatives | |
| MX341456B (es) | Amino-quinolinas como inhibidores de cinasa. | |
| NZ700612A (en) | Methods and compositions for treating ewings sarcoma family of tumors | |
| PL2681227T3 (pl) | Amidofosforanowe pochodne 5-fluoro-2'-deoksyurydyny do zastosowania w leczeniu raka | |
| MX2014003376A (es) | Derivados de acido benzoico como inhibidores eif4e. | |
| PH12015501088A1 (en) | Dimeric compounds | |
| MX2014014832A (es) | Pirrolopirimidona y pirrolopiridona, inhibidores de tanquirasa. | |
| PH12015501038A1 (en) | Inhibitors of iap | |
| MX2014008864A (es) | Derivados de triazolo[4,5-d]pirimidina. | |
| NZ597570A (en) | N1-acyl-5-fluoropyrimidinone derivatives | |
| MX349548B (es) | Compuestos de tienopirimidina. | |
| PH12015500399A1 (en) | Azaindolines | |
| AU2016204389A1 (en) | Kinase inhibitors for the treatment of cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 FEB 2017 BY CPA GLOBAL Effective date: 20160304 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 FEB 2018 BY IP CENTRUM LIMITED Effective date: 20170210 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 FEB 2019 BY IP CENTRUM LIMITED Effective date: 20180130 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 FEB 2020 BY IP CENTRUM LIMITED Effective date: 20190201 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 FEB 2021 BY IP CENTRUM LIMITED Effective date: 20200130 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 FEB 2022 BY IP CENTRUM LIMITED Effective date: 20210204 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 FEB 2023 BY IP CENTRUM LIMITED Effective date: 20220204 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 FEB 2024 BY IP CENTRUM LIMITED Effective date: 20230204 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 FEB 2025 BY IP CENTRUM LIMITED Effective date: 20240201 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 FEB 2026 BY IP CENTRUM LIMITED Effective date: 20250225 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 FEB 2027 BY IP CENTRUM LIMITED Effective date: 20260131 |